New members join the Rare Disease Action Forum

    31 Jan, 2017

    In January 2017, Alexion Pharmaceuticals, Amicus Therapeutics and Sanofi Genzyme joined the Rare Disease Action Forum (RDAF). With this growth, the Forum now includes eight member companies that are all important contributors in the field of rare diseases. Using a multi-stakeholder approach, the RDAF aims at developing and implementing solutions to improve access to diagnosis and treatment for patients with rare diseases in Switzerland. Press release (PDF): English, German, French, Italian

    Continue reading

    RDAF hosts multi-stakeholder workshop on post-marketing registries

    The Rare Disease Action Forum (RDAF) will host a multi-stakeholder workshop on post-marketing registries for rare diseases on 21 September 2023 (14.00 – 19.00 CEST) in Basel, Switzerland. The workshop will gather stakeholders active in the rare disease field to...

    RDAF Newsletter

    We just released the first issue of the RDAF newsletter, which gives an overview of key policy developments and RDAF activities in the first half of the year. Highlights include: Overview of the latest policy developments relevant for the rare disease field...